Loomis, Sayles & Company’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.2M | Buy |
217,648
+21,867
| +11% | +$1.63M | 0.02% | 274 |
|
|
2025
Q1 | $12.4M | Buy |
195,781
+31,925
| +19% | +$2.03M | 0.02% | 321 |
|
|
2024
Q4 | $12.8M | Hold |
163,856
| – | – | 0.02% | 335 |
|
|
2024
Q3 | $13.2M | Buy |
163,856
+12,310
| +8% | +$989K | 0.02% | 321 |
|
|
2024
Q2 | $12.5M | Buy |
151,546
+125,464
| +481% | +$10.4M | 0.02% | 324 |
|
|
2024
Q1 | $2.23M | Buy |
+26,082
| New | +$2.23M | ﹤0.01% | 446 |
|
|
2019
Q2 | – | Sell |
-100,637
| Closed | -$8.8M | – | 642 |
|
|
2019
Q1 | $8.8M | Buy |
100,637
+364
| +0.4% | +$31.8K | 0.02% | 371 |
|
|
2018
Q4 | $10M | Buy |
100,273
+100,161
| +89,429% | +$10M | 0.02% | 318 |
|
|
2018
Q3 | $13K | Buy |
+112
| New | +$13K | ﹤0.01% | 776 |
|
|
2018
Q1 | – | Sell |
-710
| Closed | -$41K | – | 892 |
|
|
2017
Q4 | $41K | Buy |
710
+26
| +4% | +$1.5K | ﹤0.01% | 623 |
|
|
2017
Q3 | $31K | Sell |
684
-89
| -12% | -$4.03K | ﹤0.01% | 682 |
|
|
2017
Q2 | $31K | Buy |
+773
| New | +$31K | ﹤0.01% | 681 |
|
|
2017
Q1 | – | Sell |
-770
| Closed | -$31K | – | 981 |
|
|
2016
Q4 | $31K | Buy |
+770
| New | +$31K | ﹤0.01% | 713 |
|
|
2014
Q2 | – | Sell |
-85,376
| Closed | -$2.78M | – | 754 |
|
|
2014
Q1 | $2.78M | Buy |
+85,376
| New | +$2.78M | 0.01% | 560 |
|